Key facts
- It has raised $3.2M; the latest was PE Growth/Expansion ($3.2M) in Dec 2024.
- Notable investors include SPO Capital Investments.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Audience Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Audience Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Audience Genomics
Developer of audience development, consumer insights, and data analysis services to assist clients in optimizing distribution outlets, creating better content, and building effective partnerships. The company provides insights into audience motivations and preferences, enabling content creators to make data-informed decisions and achieve greater engagement and impact.
- Sector
- Business Products and Services (B2B)
- HQ
- New York, NY, United States
- Founded
- 2018
- Website
- audiencegenomics.com/
- Ownership
- Privately Held (backing)
Audience Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Audience Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Audience Genomics in its N-PORT filings yet. We sweep new filings monthly.